Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients

Mutations and thrombosis in essential thrombocythemia

(2021) Paola Guglielmelli et al.   Blood Cancer Journal

Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

(2020) Ayalew Tefferi et al.   BRITISH JOURNAL OF HAEMATOLOGY

An agenda for future research projects in polycythemia vera and essential thrombocythemia

(2020) Tiziano Barbui et al.   HAEMATOLOGICA

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN

(2020) Camélia Benlabiod et al.   Nature Communications

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data

(2020) Giuseppe G Loscocco et al.   OncoTargets and Therapy

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values

(2019) Richard T. Silver et al.   HAEMATOLOGICA

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

(2019) Nabih Maslah et al.   HAEMATOLOGICA

Essential Thrombocythemia

(2019) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

(2018) Jacob Grinfeld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia

(2016) Yoseph C. Elala et al.   AMERICAN JOURNAL OF HEMATOLOGY

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

(2016) Giada Rotunno et al.   AMERICAN JOURNAL OF HEMATOLOGY

Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients

(2016) Mahnur Haider et al.   AMERICAN JOURNAL OF HEMATOLOGY

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

(2015) D Pietra et al.   LEUKEMIA

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

(2015) T Barbui et al.   Blood Cancer Journal

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

(2012) T. Barbui et al.   BLOOD

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

(2012) F. Passamonti et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD